InstalabLoading...
InstalabLoading...
If you keep getting sinus infections, bronchitis, or pneumonia and your doctor says your immune system looks fine on routine bloodwork, a missing piece of the puzzle might be hiding in your IgG2 (immunoglobulin G subclass 2) level. Standard lab panels measure total IgG, the main protective antibody in your blood. But total IgG can look perfectly normal even when one of its four subtypes is running low, leaving a specific gap in your defenses.
IgG2 handles a job the other subtypes are not designed for: it targets bacteria that wrap themselves in a sugar-based coating, including the common culprits behind ear infections, sinus infections, and pneumonia. When IgG2 is low, those particular bacteria gain an advantage, and you may find yourself cycling through antibiotics without ever understanding why.
Your immune system makes four versions of IgG, numbered 1 through 4. Each handles different threats. IgG2 makes up roughly one third of your total IgG and is your primary antibody against polysaccharide antigens, the sugar-based coatings found on bacteria like Streptococcus pneumoniae and Haemophilus influenzae. These are the organisms most often responsible for recurring respiratory infections.
Compared to the other subtypes, IgG2 activates the complement system (your blood's built-in bacterial destruction cascade) less efficiently and binds immune-cell receptors less tightly. That means it works through slightly different mechanisms, and its absence creates a specific blind spot rather than a total collapse of antibody function. This is why people with low IgG2 can appear immunologically normal on basic testing while still getting sick repeatedly.
The strongest clinical evidence for IgG2 testing comes from adults and children with unexplained recurrent infections of the sinuses, ears, and lungs. In a study of 236 adults with IgG subclass deficiency, those with low IgG2 had frequent upper and lower respiratory infections, often alongside other immune abnormalities such as low IgG3 or low IgA, and many showed poor responses to pneumococcal vaccination. That poor vaccine response is telling: it confirms that the IgG2 gap translates into a real functional deficit, not just a lab curiosity.
Children with selective IgG subclass deficiency show a similar pattern. Early work found that children with low IgG2 had impaired antibody responses to the sugar-based coatings on common bacteria, making them vulnerable to repeated infections despite having normal total IgG levels. When IgG2 deficiency appears alongside IgG4 deficiency, the clinical picture more closely resembles a broader immune disorder called CVID (common variable immunodeficiency), with more lower respiratory tract infections, bronchiectasis (permanent airway damage), and spleen enlargement.
In people with chronic obstructive pulmonary disease (COPD) or at risk for it, IgG2 levels predict how often the disease flares. An analysis of nearly 1,500 participants in the SPIROMICS study found that IgG2 levels below the 35th percentile were linked to more severe exacerbations, meaning that even levels within the "normal" range may signal increased vulnerability if they sit toward the lower end.
Isolated IgG2 deficiency has also been identified as an independent risk factor for exacerbations in bronchiectasis. If you have either of these lung conditions and find yourself hospitalized or on frequent antibiotics, a low IgG2 could be part of the explanation.
In a study of 106 elderly patients hospitalized with sepsis (a life-threatening response to infection), IgG2 levels independently predicted who would survive the next 28 days. Lower IgG2 in non-survivors outperformed several standard severity markers, including lactate (a waste product that builds up when tissues lack oxygen), procalcitonin (a commonly used infection marker), and both the SOFA and APACHE II scoring systems that intensive care physicians rely on. While this does not mean you should order IgG2 as a routine screening test, it shows that IgG2 carries real prognostic weight in acute immune crises.
IgG2 is not only about deficiency. Elevated IgG2, or the presence of specific IgG2 autoantibodies (antibodies that mistakenly attack your own tissues), has emerged as a marker in certain autoimmune conditions.
In systemic lupus erythematosus (SLE) and lupus nephritis (kidney inflammation from lupus), a panel of IgG2 autoantibodies targeting the body's own DNA, complement proteins, and structural proteins was highly specific for disease. Two of these markers in particular distinguished lupus nephritis from lupus without kidney involvement and correlated with disease activity in a study of over 1,000 participants.
In orbital IgG4-related disease (IgG4-RD), a condition where the immune system causes inflammation and scarring around the eyes, both serum IgG2 and tissue IgG2 levels were elevated. A serum IgG2 above 5.3 g/L (530 mg/dL) had 80% sensitivity and 91.7% specificity for distinguishing orbital IgG4-RD from other orbital inflammatory conditions.
IgG2 ranges vary meaningfully by race, sex, age, and the specific lab method used. In a study of over 12,700 adults across a large health system, average IgG2 levels differed substantially: Asian patients averaged roughly 494 mg/dL, Black patients about 384 mg/dL, and White patients about 305 mg/dL. Women tended to have slightly different subclass distributions than men. These differences mean that a "low" IgG2 by one lab's reference range might be normal for your demographic group, or vice versa.
Population-based data from nearly 8,800 middle-aged and elderly adults confirm that age, sex, smoking, alcohol use, corticosteroid exposure, and cardiovascular factors all influence immunoglobulin levels. Adjusted reference ranges may be needed for accurate interpretation.
The ranges below are approximate adult reference intervals drawn from published literature using standard laboratory methods. They are orientation, not universal targets. Your lab may report different numbers, and comparison within the same lab over time is always more meaningful than comparing a single value to a generic table.
| Tier | Range (mg/dL) | What It Suggests |
|---|---|---|
| Low | Below 169 | Possible IgG2 deficiency. Higher risk for recurrent bacterial infections, especially respiratory. Warrants follow-up with functional vaccine testing. |
| Normal | 169 to 786 | Typical adult range, though "low normal" values (below the 35th percentile for your demographic) may still carry increased infection risk in COPD or bronchiectasis. |
| Elevated | Above 786 | May be seen in chronic infections, autoimmune conditions (lupus, IgG4-related disease), or obesity and insulin resistance. Warrants clinical context. |
Always compare your results within the same lab over time. Different assay platforms can produce meaningfully different numbers for the same sample.
The single biggest analytical pitfall with IgG2 is cross-reactivity in standard immunonephelometric assays (a method that measures proteins by how much they scatter a beam of light). When IgG4 is elevated, the assay can misattribute some IgG4 to the IgG2 channel, making IgG2 appear falsely high. A telltale sign is when the sum of all four IgG subclasses exceeds the total IgG measurement. If this happens, or if IgG4-related disease is suspected, confirmation by a more precise method called LC-MS/MS (liquid chromatography-tandem mass spectrometry, a technique that separates molecules more accurately) is recommended.
Body weight and metabolic status can also shift IgG2 independently of immune function. In a study of 262 non-diabetic adults, IgG2 was positively correlated with BMI, waist circumference, and markers of inflammation, and was independently associated with lower insulin sensitivity. If your IgG2 is mildly elevated and you carry extra weight or have early insulin resistance, the elevation may reflect metabolic inflammation rather than an immune problem.
A single IgG2 measurement is a snapshot, and snapshots can mislead. Modern laboratory assays for IgG subclasses are reasonably precise when run on the same platform, but variation between different labs and assay methods can be substantial. That means if your IgG2 shifts meaningfully between two draws taken at the same lab under similar conditions, it is more likely to reflect a real biological change than measurement noise.
The practical approach: get a baseline measurement when you are clinically stable (no active infection, no recent steroid course, consistent medications). If the result is borderline or low, retest in 6 to 12 weeks under the same conditions. At least two consistent measurements are needed before drawing firm conclusions. If you are making changes, such as starting immunoglobulin replacement or stopping a medication that suppresses IgG2, recheck at 3 to 6 months to confirm the intervention is working, then annually to monitor your trend.
If your IgG2 comes back low, the next step is context. First, rule out confounders: are you taking carbamazepine, an MS therapy, or corticosteroids? Were you recently ill? If the low result persists on a repeat draw, the standard workup is to check all four IgG subclasses (IgG1, IgG2, IgG3, IgG4), total IgG, IgA, and IgM, followed by a functional test of your antibody response to pneumococcal polysaccharide vaccine (PPSV23). A poor vaccine response alongside low IgG2 confirms a real functional gap, not just a number on a page.
If both the level and the functional response are abnormal, referral to an immunologist is warranted. They can determine whether you have an isolated IgG subclass deficiency, a broader antibody deficiency resembling CVID, or a secondary cause such as medication or an underlying blood disorder. Treatment options, including immunoglobulin replacement therapy, can dramatically reduce infection frequency when deficiency is confirmed.
If your IgG2 is elevated, the clinical question shifts to why. An immunologist or rheumatologist can help distinguish between chronic infection, autoimmune disease (particularly lupus or IgG4-related disease), and metabolic inflammation. Companion tests like ANA (antinuclear antibody), anti-dsDNA antibodies, IgG4, complement C3 and C4, and inflammatory markers like hs-CRP (high-sensitivity C-reactive protein) can help narrow the diagnosis.
Evidence-backed interventions that affect your IgG2 level
IgG2 is best interpreted alongside these tests.